


Wessex first line treatment of MCL.

Offer clinical trial if available [Lymphoma Trials](#) | [Wessex Haematology Network](#)



For MDT:
Histology
PET CT
mIPI & TP53 mutation

1. High risk – any of TP53 mutated, Ki67>30%, blastoid/pleomorphic histology.
2. No overall survival benefit. Dreyling et al. JCO 2025.

*Offer ibrutinib during the R-CHOP component of R-CHOP/R-DHAP induction and for 2 years maintenance in place of ASCT if licensed and reimbursed in this setting
^ Do not offer maintenance rituximab